IMMUNOCORE HLDGS ADS/1 (F:6YG) — Stock Price
IMMUNOCORE HLDGS ADS/1 (F:6YG) is currently trading at €24.80 EUR, down 1.59% today. Over the past 52 weeks, shares have ranged between €24.60 and €34.60. This page tracks IMMUNOCORE HLDGS ADS/1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 6YG market cap overview.
IMMUNOCORE HLDGS ADS/1 (6YG) Stock Price Chart — Daily History & Trading Volume
The chart below tracks IMMUNOCORE HLDGS ADS/1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
IMMUNOCORE HLDGS ADS/1 Income Statement — Revenue, Profit & Earnings by Year
IMMUNOCORE HLDGS ADS/1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | €400.02 Million | €310.20 Million | €249.43 Million | €174.36 Million |
| Cost of Revenue | €5.09 Million | €2.73 Million | €1.04 Million | €1.09 Million |
| Gross Profit | €394.93 Million | €307.47 Million | €248.39 Million | €173.27 Million |
| Research & Development | €274.87 Million | €222.15 Million | €163.54 Million | €101.92 Million |
| SG&A | €165.41 Million | €155.78 Million | €144.50 Million | €123.06 Million |
| Total Operating Expenses | €445.37 Million | €380.66 Million | €309.08 Million | €226.07 Million |
| Operating Income | €-45.35 Million | €-70.46 Million | €-59.65 Million | €-51.71 Million |
| EBITDA | — | — | — | — |
| EBIT | — | — | — | — |
| Interest Expense | €12.17 Million | €18.84 Million | €5.15 Million | €5.41 Million |
| Income Before Tax | €-19.10 Million | €-52.94 Million | €-60.89 Million | €-40.88 Million |
| Income Tax Expense | — | — | — | — |
| Net Income | €-35.51 Million | €-51.09 Million | €-55.29 Million | €-52.54 Million |
IMMUNOCORE HLDGS ADS/1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes IMMUNOCORE HLDGS ADS/1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | €1.07 Billion | €1.01 Billion | €597.00 Million | €526.76 Million |
| Total Current Assets | €996.74 Million | €929.86 Million | €528.82 Million | €473.98 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | €396.44 Million | €364.64 Million | €0.00 | — |
| Net Receivables | €73.98 Million | €63.01 Million | €52.09 Million | €33.58 Million |
| Inventory | €6.74 Million | €5.45 Million | €4.50 Million | €692.00K |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | €686.24 Million | €648.79 Million | €228.16 Million | €187.86 Million |
| Total Current Liabilities | €246.70 Million | €212.18 Million | €139.02 Million | €100.83 Million |
| Long-term Debt | €393.12 Million | €391.01 Million | €48.01 Million | €47.81 Million |
| Net Debt | — | — | — | — |
| Total Stockholder Equity | €381.03 Million | €360.72 Million | €368.84 Million | €338.90 Million |
| Retained Earnings | €-831.27 Million | €-795.76 Million | €-744.67 Million | €-689.39 Million |
IMMUNOCORE HLDGS ADS/1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how IMMUNOCORE HLDGS ADS/1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | €-10.71 Million | €26.06 Million | €2.94 Million | €-49.21 Million |
| Capital Expenditures | €4.34 Million | €5.17 Million | €5.42 Million | €2.20 Million |
| Free Cash Flow | €-15.05 Million | €20.89 Million | €-2.48 Million | €-51.41 Million |
| Investing Cash Flow | — | — | — | — |
| Financing Cash Flow | €12.37 Million | €343.88 Million | €34.35 Million | €145.44 Million |
| Dividends Paid | — | — | — | €0.00 |
| Stock-Based Compensation | €37.70 Million | €34.19 Million | €32.47 Million | €32.89 Million |
| Depreciation | €3.27 Million | €4.20 Million | €4.09 Million | €5.33 Million |
| Change in Cash | €-14.68 Million | €14.81 Million | €31.86 Million | €94.04 Million |
IMMUNOCORE HLDGS ADS/1 Earnings History — EPS Actual vs. Analyst Estimates
Track IMMUNOCORE HLDGS ADS/1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 06, 2026 | — | -0.23 | — |
| May 06, 2026 | — | -0.25 | — |
| Feb 25, 2026 | — | -0.19 | — |
| Nov 05, 2025 | — | -0.24 | — |
| Aug 06, 2025 | — | — | — |
| May 06, 2025 | — | — | — |
| Feb 26, 2025 | — | — | — |
| Nov 05, 2024 | — | — | — |